Thomas Coogan Neylan MD
Professor of Psychiatry, In Residence; Director of PTSD Research; Deputy Associate Chief of Staff for Research at VAMC
Join to View Full Profile
4150 Clement StVamc 116pSan Francisco, CA 94121
Phone+1 415-750-6961
Dr. Neylan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationResidency, Psychiatry, 1986 - 1989
University of Pennsylvania Health SystemResidency, Psychiatry, 1984 - 1986
Rush Medical College of Rush University Medical CenterClass of 1984
Certifications & Licensure
CA State Medical License 1988 - 2026
PA State Medical License 1986 - 1994
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia Start of enrollment: 2008 Nov 01
- Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder Start of enrollment: 2003 Feb 01
- Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance Start of enrollment: 2011 May 01
- Join now to see all
Publications & Presentations
PubMed
- Reliable symptom worsening among veterans receiving cognitive processing therapy or prolonged exposure therapy for posttraumatic stress disorder in routine Veterans He...Nicholas Holder, Adam Batten, Brian Shiner, Thomas C Neylan, Shira Maguen
Journal of Affective Disorders. 2025-10-15 - The reciprocal relationship between posttraumatic stress disorder symptoms and alcohol use in a large multisite longitudinal sample stratified by sex: A random-interce...Cecilia A Hinojosa, Sanne J H van Rooij, Negar Fani, Robyn A Ellis, Henri M Garrison-Desany
Alcohol, Clinical & Experimental Research. 2025-06-06 - Sequential decreases in basolateral amygdala response to threat predict failure to recover from PTSD.Alyssa R Roeckner, Esther R-H Lin, Rebecca Hinrichs, Nathaniel G Harnett, Lauren A M Lebois
Neuropsychopharmacology. 2025-05-03
Authored Content
- The Role of Co-Neurotransmitters in Sleep and Wake RegulationOctober 2018
- The Role of Co-Neurotransmitters in Sleep and Wake RegulationOctober 2018
- Posttraumatic Stress Disorder, Depression, and Suicidal Ideation in Veterans: Results from the Mind Your Heart StudyApril 2018
- F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
- The Effects of Early Trauma and the FKBP5 Gene on PTSD and the HPA Axis in a Clinical Sample of Gulf War Veterans☆March 2018
- Join now to see all
Press Mentions
New Insights into Why Alzheimer's Can Bring DrowsinessApril 9th, 2022- New Insights into Why Alzheimer's Can Bring DrowsinessApril 8th, 2022
- Sleepiness in Alzheimer’s Disease Due to Loss of Wake-Promoting NeuronsApril 5th, 2022
- Join now to see all
Grant Support
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- Investigating Fear System Myelination in PTSD Using In Vivo and Post Mortem DataNORTHERN CALIFORNIA INSTITUTE/RES/EDU2023–2028
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)VETERANS AFFAIRS MED CTR SAN FRANCISCO2022–2025
- Examining the Effect of Sleep Disruption on Emotion Regulation and Trauma-Related Symptoms in VeteransVETERANS AFFAIRS MED CTR SAN FRANCISCO2020–2025
- Examining the Effect of Sleep Disruption on Emotion Regulation and Trauma-Related Symptoms in VeteransVETERANS AFFAIRS MED CTR SAN FRANCISCO2020–2025
- Examining the Effect of Sleep Disruption on Emotion Regulation and Trauma-Related Symptoms in VeteransVETERANS AFFAIRS MED CTR SAN FRANCISCO2020–2025
- Examining the Effect of Sleep Disruption on Emotion Regulation and Trauma-Related Symptoms in VeteransVETERANS AFFAIRS MED CTR SAN FRANCISCO2020–2025
- Examining the Effect of Sleep Disruption on Emotion Regulation and Trauma-Related Symptoms in VeteransVETERANS AFFAIRS MED CTR SAN FRANCISCO2020–2025
- Linking Sleep Dysfunction to Tau-related Degeneration across AD ProgressionUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2025
- Individual Variation in Effects of Traumatic Stress on Gray Matter MyelinNORTHERN CALIFORNIA INSTITUTE/RES/EDU2019–2025
- Cognitive Behavioral Treatment Of Insomnia In Posttraumatic Stress DisorderNational Institute Of Mental Health2008–2010
- Neuroendocrine Regulation Of Sleep In PTSDNational Institute Of Mental Health2005–2008
- Sleep And Hypothalamic Pituitary Adrenal Function In PTSDNational Center For Research Resources2004
- Sleep &Hypothalamic Pituitary Adrenal Function In PTSDNational Center For Research Resources2000–2002
- Sleep And Arousal Disturbances In PTSDNational Institute Of Mental Health1998–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
